Ken Griffin
CRNX icon

Ken Griffin’s Crinetics Pharmaceuticals CRNX Stock Holding History

Ken Griffin’s Portfolio CRNX Stock Details CRNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$370K Buy
10,200
+200
+2% +$8.93K ﹤0.01% 9985
2025
Q4 		$466K Sell
10,000
-28,200
-74% -$1.26M ﹤0.01% 9196
2025
Q3 		$1.59M Buy
38,200
+23,500
+160% +$751K ﹤0.01% 6533
2025
Q2 		$423K Buy
14,700
+3,100
+27% +$95.7K ﹤0.01% 9020
2025
Q1 		$389K Buy
11,600
+4,000
+53% +$149K ﹤0.01% 9023
2024
Q4 		$389K Sell
7,600
-11,600
-60% -$649K ﹤0.01% 9117
2024
Q3 		$981K Buy
19,200
+15,700
+449% +$810K ﹤0.01% 6904
2024
Q2 		$157K Sell
3,500
-28,100
-89% -$1.3M ﹤0.01% 10278
2024
Q1 		$1.48M Buy
31,600
+21,300
+207% +$833K ﹤0.01% 6113
2023
Q4 		$366K Sell
10,300
-72,300
-88% -$2.22M ﹤0.01% 8741
2023
Q3 		$2.46M Buy
82,600
+78,300
+1,821% +$1.61M ﹤0.01% 4849
2023
Q2 		$77.5K Buy
4,300
+4,200
+4,200% +$83.8K ﹤0.01% 11279
2023
Q1 		$1.61K Sell
100
-1,000
-91% -$18.5K ﹤0.01% 14272
2022
Q4 		$20.1K Buy
+1,100
New +$19.4K ﹤0.01% 13140

Other funds holding CRNX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Ken Griffin's CRNX Position: Q1 2026 in Review

Ken Griffin increased its Crinetics Pharmaceuticals (CRNX) stake by 25% in Q1 2026, buying an estimated $2.82M and bringing the position to 317,934 shares worth $11.5M. The position accounts for ﹤0.01% of the portfolio, ranked #3055.

Ken Griffin first reported a position in CRNX in Q2 2019 and has held it in 26 quarters since. The position peaked at $36.8M in Q3 2025. 243 funds tracked by Wall St. Rank hold CRNX as of Q1 2026.

  • Ken Griffin held 317,934 shares of Crinetics Pharmaceuticals worth $11.5M as of Q1 2026.
  • Ken Griffin bought 63,214 Crinetics Pharmaceuticals shares in Q1 2026, an estimated $2.82M.
  • Crinetics Pharmaceuticals made up ﹤0.01% of Ken Griffin's portfolio in Q1 2026, its #3055 holding.
  • Ken Griffin first reported a position in Crinetics Pharmaceuticals in Q2 2019 and has held it in 26 quarters since.
  • Ken Griffin's Crinetics Pharmaceuticals position peaked at $36.8M in Q3 2025.
  • 243 funds tracked by Wall St. Rank held Crinetics Pharmaceuticals as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.